高危前列腺癌患者接受根治性放疗相比根治性前列腺切除术具有更优的无转移生存:倾向性评分匹配分析
本研究报告了在本机构2002至2011年间接受治疗的局限性高危前列腺癌患者的倾向性评分匹配分析,共62对匹配患者。根治性放疗组5年转移率为8.9%,根治性前列腺切除术组为33%(P=0.003),总生存无差异。
要点
- 根治性放疗组5年转移率为8.9%,根治性前列腺切除术组为33%(P=0.003)。
- 两组总生存无差异。
- 根治性放疗组挽救治疗延迟时间更长(P<.001)。
核心结论
- 在本机构,根治性放疗相比根治性前列腺切除术获得了更优的无转移生存,但未伴随总生存的改善。
研究设计与样本
- 回顾性审查了2002年至2011年在本机构接受治疗的局限性高危前列腺癌患者的医疗记录。
- 共识别246例患者,经倾向性评分匹配后形成62对匹配患者。
- 匹配因素包括年龄、成人合并症评估-27合并症指数、前列腺特异性抗原、穿刺活检Gleason评分和临床T分期。
主要发现
- 根治性前列腺切除术组和根治性放疗组的5年转移率分别为33%和8.9%(P=0.003)。
- 总生存无差异。
- 根治性放疗组挽救治疗延迟时间更长(P<.001)。
- 根治性前列腺切除术组和根治性放疗组分别有6.5%和80.6%的患者接受了雄激素剥夺治疗。
- 仅比较未接受雄激素剥夺治疗的患者时,结果相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: For high-risk prostate cancer (HR-PCa) in men with a life expectancy of at least 10 years, the National Comprehensive Cancer Network recommends radiation therapy (RT) plus androgen deprivation therapy (ADT) with category 1 evidence or radical prostatectomy (RP) as an acceptable initial therapy. Randomized evidence regarding which therapy is optimal for disease control is lacking for men with HR-PCa. We performed a propensity-score-matched comparison of outcomes for men with localized HR-PCa treated with primary RT or RP. METHODS AND MATERIALS: The medical records of patients with localized HR-PCa who were treated at our institution between 2002 and 2011 were reviewed. Patient and disease characteristics, treatment details, and outcomes were collected. A combination of nearest-neighbor propensity score matching on age, Adult Comorbidity Evaluation-27 comorbidity index, prostate-specific antigen, biopsy Gleason scores, and clinical T-stage as well as exact matching on prostate-specific antigen, biopsy Gleason scores, and clinical T-stage was performed. Outcomes were measured from diagnosis. Multivariate Cox proportional hazards regression was used to compare metastasis-free and overall survival. RESULTS: A total of 246 patients were identified with 62 propensity-score-matched pairs. ADT was administered to 6.5% and 80.6% of patients receiving RP and RT, respectively. Five-year rates of metastasis for RP and RT were 33% and 8.9%, respectively (P = .003). Overall survival was not different. Delay of salvage therapy was longer for patients undergoing primary RT (P < .001). Findings were similar when only those patients who did not receive ADT were compared. CONCLUSIONS: At our institution, treatment with primary RT resulted in superior metastasis-free survival over RP. This was not accompanied by an improvement in OS.
引用
- Markovina S, Meeks MW, Badiyan S, et al. Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis. Adv Radiat Oncol. 2017. PMID: 29904744. doi:10.1016/j.adro.2017.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。